Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASAP: Avelumab and Paclitaxel in Inoperable Angiosarcoma
NCT03512834Phase 2Unknown
- Start
- Jun 2018
- Primary completion
- Nov 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of avelumab in angiosarcoma. Status: unknown.
02
Drugs
avelumab
03
Conditions
angiosarcoma
Beyond the preview
Go deeper on NCT03512834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03512834.